Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Breakthrough Diagnostic Approach to Significantly Improve TB Detection

By LabMedica International staff writers
Posted on 24 Apr 2025

Tuberculosis (TB) remains the deadliest infectious disease globally, with 10. More...

8 million new cases and 1.25 million deaths reported in 2023. Early detection through effective screening is crucial in identifying TB, preventing its spread, and ultimately working towards its eradication. TB can remain dormant in the body for years without causing symptoms, but it may become active later, particularly in individuals at high risk. Therefore, accurate testing for both active and dormant TB infections is critical for effective screening programs. Current TB testing methods include chest X-rays, sputum cultures, molecular tests, symptom screenings, and skin or blood tests to detect dormant TB infections (TBI). All these methods aim to accurately identify TB with minimal false positives to avoid unnecessary treatments. Now, a new strategy for TB screening addresses the limitations of existing methods, which often fail to detect the disease accurately.

Simultaneously screening for both active and dormant TB infections could significantly reduce infection rates, save lives, and alter the ongoing spread of the disease, according to a new study by researchers at Queen Mary University of London (QMUL, London, UK). The researchers hope that this novel approach, detailed in the European Respiratory Journal, will influence global health organizations and policymakers in defining the most effective screening strategies for TB. In the study, the research team evaluated the effectiveness of combining commonly used TB tests. Their study reviewed data from 437 original studies and published systematic reviews involving 13 different TB tests. The collected data were used to assess the accuracy of these screening tests in both detecting TB and minimizing false positives.

Unlike previous studies, the researchers found that incorporating some immunological tests for dormant TB infection (TBI tests) improved the screening process. These tests could enhance early diagnosis, particularly for harder-to-detect forms of TB, including extrapulmonary TB (which affects parts of the body outside the lungs) and TB in children. This innovative approach challenges traditional TB testing protocols, which generally reserve TBI tests solely for diagnosing dormant TB. Crucially, combining diagnostic tests for both active and dormant TB allows for the detection of both forms of the disease at the same time. This opportunity for enhanced detection across large populations is particularly valuable to policymakers and public health organizations such as the World Health Organization (WHO) and the European Centre for Disease Prevention and Control.

"Global TB control requires early identification and treatment of TB in risk groups,” said Dr. Dominik Zenner, Clinical Reader in Infectious Disease Epidemiology at Queen Mary who led the research team. “Our novel screening algorithms show that screening for active and dormant TB can be done simultaneously with high accuracy for migrants from countries where TB is common to improve individual and population benefits.”


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automatic CLIA Analyzer
Shine i6000
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.